ASLN’s ‘004 is a fast follower, targeting an understood, de-risked path in atopic dermatitis [eczema],’ said Jefferies analyst Maury Raycroft.
( read original story …)
Search your Hotel
The Singapore News
ASLN’s ‘004 is a fast follower, targeting an understood, de-risked path in atopic dermatitis [eczema],’ said Jefferies analyst Maury Raycroft.
( read original story …)
Search your Hotel